An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

NCT04659174 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

152

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Xanomeline and Trospium Chloride Capsules

Sponsor

Karuna Therapeutics, Inc., a Bristol Myers Squibb company